Peptides in Canada: From Insulin to the 2026 Research Landscape

Canada's relationship with peptides did not begin with an online storefront. It began in a Toronto laboratory in the summer of 1921, and the thing that came out of that laboratory is still the most consequential peptide drug ever made.

That history matters for a practical reason. Insulin is the proof that a short chain of amino acids can be a medicine, and the century since is the record of how hard it is to get one from a bench to a pharmacy. This page is about that record: what Canada actually approves, what it does not, where peptide research is done here, and what separates the tier of material a regulator has reviewed from the tier that is sold for laboratory work.

If what you want is purchasing guidance, that is a different question and it has its own pages: Where to Buy Peptides in Canada Online for vendor evaluation, and The Complete Guide to Buying Peptides in Canada for the full procurement picture. This page deliberately does not repeat them.

The Toronto Discovery That Made Peptide Medicine Possible

Work began in May 1921. Frederick Banting and Charles Best, in space provided by J.J.R. Macleod at the University of Toronto, isolated a pancreatic extract that lowered blood glucose in depancreatised dogs. The extract was crude and it was not safe to give to a person. James Collip, a biochemist, did the purification that made it usable.

Leonard Thompson, fourteen years old and dying of diabetes at Toronto General Hospital, received the first injection on 11 January 1922. It produced an abscess and little benefit. He received Collip's purified extract on 23 January, and that one worked. The Nobel Prize in Physiology or Medicine followed in 1923.

The part most often left out is the patent. Banting, Best and Collip assigned it to the University of Toronto for one dollar each, and the university licensed it broadly rather than exclusively so that supply would scale and prices would stay low. Banting's reported line was that insulin did not belong to him, it belonged to the world.

Two things about this are worth carrying forward. First, the hard part was never the discovery. It was purification, consistency between batches, and demonstrating that a given vial contained what the label said. Those are the same three problems that define peptide quality today, which is why a Certificate of Analysis is the document that matters and a purity claim without a method behind it is not. Second, insulin is a peptide hormone that had to go through a century of manufacturing science to become the routine product it now is. That distance is exactly the gap between an approved drug and a research chemical.

What Canada Actually Approves

Under the Food and Drugs Act, a substance sold or represented for use in diagnosing, treating, mitigating or preventing disease, or for modifying organic functions, is a drug. Reaching the market means a submission to Health Canada, a review of safety, efficacy and quality, a Notice of Compliance, and a Drug Identification Number.

The DIN is the practical test, and it is public. Health Canada's Drug Product Database lets anyone check whether a specific product is authorised, who holds the authorisation and what it is authorised for. Approved peptide and peptide-analogue drugs in Canada include the insulins, GLP-1 receptor agonists such as semaglutide and liraglutide, the dual GIP/GLP-1 agonist tirzepatide, parathyroid hormone analogues, somatostatin analogues such as octreotide, GnRH analogues such as leuprolide, desmopressin and calcitonin. That list is short, specific, and checkable, which is the point.

The 2026 generic semaglutide sequence

Canada moved faster than any comparable regulator here, and the sequence is worth stating precisely because it is widely garbled.

At the time of the June announcement Health Canada said Sevmia was the third generic semaglutide it had approved, that six further submissions from other companies were under review, and that generic medicines in Canada typically run 45 to 90% cheaper than the brand versions.

Tirzepatide is a different situation: it remains under patent protection well into the next decade, so no generic exists. Oral semaglutide is authorised in Canada as a tablet, which is unusual for a peptide, since peptides are normally destroyed in the gut before absorption.

The broader point for anyone reading a vendor's marketing: the compounds with the strongest evidence and the clearest regulatory status are precisely the ones you can buy through a pharmacy with a prescription. A supplier implying that a research vial is the same product at a lower price is describing something that is not true of the regulatory system.

The Unapproved Tier, and Why Health Canada Is Acting

Alongside the approved list is a much larger set of compounds sold without authorisation. Health Canada's public advisory of 9 April 2026 named a specific group circulating in this market: BPC-157, CJC-1295, DSIP, epitalon, GHK-Cu, HCG, ipamorelin, KPV, melanotan I and II, MOTS-c, NAD+, SS-31, TB-500 and retatrutide.

The advisory says two things that get misquoted constantly. It states that Health Canada has seized unauthorized injectable peptide drugs and is working with the Canada Border Services Agency to stop unauthorized shipments entering the country. And on labelling, it states that "research use only" marking "does not make these products legal or exempt from regulatory requirements."

Health Canada has also named individual sellers in advisories, including operations trading as Canada Peptide, Prime Research and Canlab Research, and has obtained an injunction against an unauthorized retailer. Those are public records, searchable by company name in the recalls and advisories database.

None of that makes laboratory research illegitimate. It means the regulatory status of a compound and its usefulness as a research reagent are separate questions, and conflating them is what gets vendors named. Our regulations hub and the Canada page cover the framework; the regulatory status checker gives per-compound status and the recall tracker surfaces published advisories.

How a Peptide Becomes a Drug in Canada

The path from a promising sequence to a DIN is long enough that understanding it explains most of the price gap between tiers.

1. Discovery and preclinical work. Sequence design, synthesis, in-vitro characterisation, animal pharmacology and toxicology. This is the stage research-grade material actually serves.
2. Clinical Trial Application. A CTA goes to Health Canada before any human study. Approval is required to begin.
3. Phase I to III. Safety and pharmacokinetics, then efficacy and dose-finding, then large controlled trials.
4. New Drug Submission. The full dossier: clinical data, chemistry and manufacturing, proposed labelling.
5. Notice of Compliance and DIN. Authorisation to market, and the number that makes the product identifiable in the Drug Product Database.
6. Post-market surveillance. Adverse reaction reporting and ongoing monitoring.

Manufacturing sits underneath all of it. A drug submission requires Good Manufacturing Practice production with validated analytical methods, documented batch records and stability data. That is a different world from research-grade synthesis, and it is most of the cost. The three grades of material are compared in detail in the buying guide.

Where Peptide Research Happens in Canada

Canadian peptide work is concentrated in the universities and the federal research system rather than in a domestic pharmaceutical giant.

The University of Toronto remains central, for historical reasons and because the diabetes and metabolism research built around the insulin legacy never went away. UBC, McGill, McMaster and the University of Alberta all run relevant programmes across structural biology, protein chemistry and metabolic research. The National Research Council's human health therapeutics work covers biologics development and analytical capability. Funding runs largely through CIHR and NSERC, with provincial agencies adding to it.

Practically, that means Canadian peptide research is heavily academic and heavily analytical. It is method development, mechanism work, structural characterisation and preclinical pharmacology, not late-stage clinical development. That shapes what research-grade material is actually used for here: in-vitro assays, receptor binding studies, analytical method validation and reference comparisons, where identity and purity matter more than sterility or endotoxin load.

If you want to judge the evidence behind a specific compound rather than take a vendor's summary of it, the research literacy guide covers study design and the evidence grade calculator scores what a claim actually rests on. The myths guide addresses the claims that circulate hardest without support.

What Research-Grade Material Is Actually For

This is where most confusion in the Canadian market lives, so it is worth being blunt.

Research-grade peptide is a laboratory reagent. It is characterised for identity and purity, usually by HPLC and ideally by mass spectrometry, and it is appropriate for in-vitro work, screening, method development and preclinical study. Our quality page sets out the ≥98% HPLC standard we hold and the COA library publishes the batch reports behind it, including the measured quantity per vial rather than only a purity percentage.

It is not a certified reference standard, which carries a certified quantitative value with a stated uncertainty and costs one to two orders of magnitude more. It is not GMP material, which requires an inspected facility and a full batch record. And it is not an approved drug, which requires everything above plus clinical evidence and a Notice of Compliance.

Those four tiers answer four different questions. A supplier that blurs them is not offering you a bargain, it is describing a product that does not exist.

Where This Leaves a Canadian Researcher

The country that gave insulin to the world for three dollars now has an unusually clear two-tier picture. On one side, an approved-drug system that moved faster than any G7 peer on generic semaglutide and publishes every authorisation in a database you can search. On the other, a research-chemical market that a regulator is actively policing at the border and naming sellers in.

Working cleanly in the second tier means being precise about what your material is, documenting it, and not borrowing the first tier's language for it. That is the whole discipline, and it is not complicated.

• Where to Buy Peptides in Canada Online: supplier evaluation, red flags and the border position.
• The Complete Guide to Buying Peptides in Canada: grades of material, analytics, landed cost and storage.
• Peptide Regulations by Country: the legal picture beyond Canada.
• Quality and Testing: our purity standard and how batches are verified.
• Research Tools: calculators for purity, mass, net peptide content and storage.

Frequently Asked Questions

Was insulin really discovered in Canada?

Yes. It was isolated at the University of Toronto beginning in May 1921 by Frederick Banting and Charles Best, working under J.J.R. Macleod, with James Collip performing the purification that made it safe to administer. Leonard Thompson received the first injection on 11 January 1922 and Collip's purified extract on 23 January. The Nobel Prize followed in 1923, and the patent was assigned to the University of Toronto for one dollar each.

Which peptide drugs are approved in Canada?

Approved peptide and peptide-analogue drugs include the insulins, GLP-1 receptor agonists such as semaglutide and liraglutide, the dual GIP/GLP-1 agonist tirzepatide, parathyroid hormone analogues, somatostatin analogues such as octreotide, GnRH analogues such as leuprolide, desmopressin and calcitonin. The authoritative check is Health Canada's Drug Product Database, which lists every product holding a Drug Identification Number.

Is generic semaglutide available in Canada?

Yes. On 28 April 2026 Canada became the first G7 country to approve a generic semaglutide. Health Canada approved an Apotex generic for adults with type 2 diabetes on 1 May 2026, and on 29 June 2026 authorised Sevmia, an Apotex generic of Wegovy and the first generic approved for chronic weight management, for patients 12 and over. Six further submissions were under review at that point.

Is tirzepatide available as a generic in Canada?

No. Tirzepatide remains under patent protection well into the next decade, so no generic version exists in Canada or elsewhere. Any product marketed as generic tirzepatide is not an authorised generic.

What does a Drug Identification Number tell me?

A DIN means Health Canada reviewed a submission for that specific product and authorised it for a specific use. It identifies the manufacturer, the product, the strength and the product form, and it is searchable in the public Drug Product Database. The absence of a DIN means the product has not been through that review, whatever else is claimed for it.

Does "research use only" have legal meaning in Canada?

It describes an intended application, not a legal exemption. Health Canada's April 2026 public advisory states directly that this labelling "does not make these products legal or exempt from regulatory requirements." The regulator has seized unauthorized injectable peptide products, named individual sellers in advisories, and stated that it is working with the Canada Border Services Agency on shipments entering the country.

What is research-grade peptide actually appropriate for?

In-vitro laboratory work: assays, receptor binding studies, analytical method development and validation, and preclinical characterisation, where compound identity and purity are the properties that matter. It is not a certified reference standard, not GMP material, and not a substitute for an authorised medicine. Those are four separate tiers answering four separate questions.

Where is peptide research done in Canada?

Mostly in universities and the federal research system rather than a domestic pharmaceutical industry. The University of Toronto remains central for historical and ongoing metabolic research reasons, with substantial programmes at UBC, McGill, McMaster and the University of Alberta, and biologics development capability at the National Research Council. Funding runs principally through CIHR and NSERC.